Internal Medicine, Hematology & Oncology · Tulsa, OK
NPI
1346351004
Since 2006
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
2
Medicare group memberships
Hospitals
5
Hospital affiliations
12697 E 51st St
Tulsa, OK, 74146
Phone (918) 505-3200
Groups this clinician bills Medicare through
Medicare paid, 2024
$4.1M
217,804 services
Medicare patients, 2024
1,357
Average age 74
Drug cost, 2024
$9.4M
2,996 prescriptions
Company payments, 2025
$1,535
From 25 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Scott Cole was code J1439 (injection, ferric carboxymaltose, 1 mg), 19,500 times for 25 patients. In total Scott Cole billed 217,804 services in 237 codes, and Medicare paid $4.1M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2014-05-09.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J1439 Injection, ferric carboxymaltose, 1 mg | Office | 19,500 | 25 | $0.87 | $17K |
| Q9967 Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | Office | 16,160 | 155 | $0.10 | $1,574 |
| J9299 Injection, nivolumab, 1 mg | Office | 14,720 | 22 | $24.53 | $361K |
| J9267 Injection, paclitaxel, 1 mg | Office | 10,092 | 39 | $0.08 | $809 |
| J9271 Injection, pembrolizumab, 1 mg | Office | 10,000 | 30 | $44.61 | $446K |
| J1627 Injection, granisetron, extended-release, 0.1 mg | Office | 9,400 | 65 | $4.40 | $41K |
| J9144 Injection, daratumumab, 10 mg and hyaluronidase-fihj | Office | 9,360 | 27 | $39.02 | $365K |
| J9263 Injection, oxaliplatin, 0.5 mg | Office | 7,000 | 16 | $0.05 | $379 |
| J0185 Injection, aprepitant, 1 mg | Office | 4,940 | 28 | $1.34 | $6,605 |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 3,496 | 181 | $0.09 | $311 |
| J0881 Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 3,430 | 12 | $2.35 | $8,063 |
| J1453 Injection, fosaprepitant, 1 mg | Office | 3,300 | 14 | $0.11 | $366 |
| J1449 Injection, eflapegrastim-xnst, 0.1 mg | Office | 3,168 | 18 | $21.31 | $67K |
| J1930 Injection, lanreotide, 1 mg | Office | 2,760 | 15 | $38.22 | $106K |
| 85025 Blood Count | Office | 2,720 | 568 | $7.58 | $21K |
By year: 2022 $3.2M for 182,257 services; 2023 $3.5M for 203,852 services; 2024 $4.1M for 217,804 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 85025 Blood Count | 2,720 | 568 | $7.58 | $21K |
| 80053 Clinical Chemistry | 2,706 | 572 | $10.31 | $28K |
| 84100 Clinical Chemistry | 2,680 | 561 | $4.63 | $12K |
| 83615 Clinical Chemistry | 2,679 | 561 | $5.90 | $16K |
| 84550 Clinical Chemistry | 2,679 | 562 | $4.41 | $12K |
| 83735 Clinical Chemistry | 2,677 | 560 | $6.55 | $18K |
| 36415 Venipuncture Blood Collection | 1,824 | 509 | $8.64 | $16K |
| 84443 Clinical Chemistry | 331 | 94 | $16.46 | $5,448 |
| 82378 Clinical Chemistry | 317 | 89 | $18.48 | $5,857 |
| 88185 Surgical Pathology Examination | 247 | 11 | $16.44 | $4,060 |
Medicare prescription drug claims, 2024
In 2024, the drug Scott Cole prescribed most often to Medicare patients was Letrozole, with 462 prescriptions and refills. In total Scott Cole wrote 2,996 Medicare prescriptions that cost $9.4M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Letrozole Generic | 462 | 948 | 113 | $11K |
| Prochlorperazine Maleate Generic | 127 | 127 | 85 | $1,802 |
| Ondansetron Hcl Generic | 119 | 121 | 75 | $972 |
| Exemestane Generic | 97 | 159 | 21 | $8,640 |
| Anastrozole Generic | 94 | 203 | 28 | $3,518 |
| Levothyroxine Sodium Generic | 93 | 141 | 23 | $471 |
| Potassium Chloride Generic | 85 | 135 | 27 | $992 |
| Eliquis Apixaban | 80 | 94 | 19 | $54K |
| Levofloxacin Generic | 78 | 78 | 74 | $363 |
| Oxycodone Hcl Generic | 74 | 76 | 31 | $1,220 |
| Tamoxifen Citrate Generic | 68 | 136 | 18 | $1,798 |
| Hydroxyurea Generic | 67 | 102 | 17 | $1,564 |
| Ondansetron Odt Ondansetron | 64 | 64 | 36 | $1,458 |
| Cabometyx Cabozantinib S-Malate | 60 | 60 | Under 11 | $1.2M |
| Olanzapine Generic | 58 | 80 | 20 | $571 |
Brand drugs: 732 claims; generic drugs: 2,264 claims; opioid claims: 204.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Scott Cole $1,535 ($1,535 in general payments such as food, travel and fees) from 25 companies. The largest payer was AstraZeneca Pharmaceuticals LP with $280.
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP AZN | 4 | $280 |
| Daiichi Sankyo Inc. 4568.T | 3 | $168 |
| Pfizer Inc. PFE | 16 | $164 |
| Caris MPI, Inc. | 2 | $141 |
| Novartis Pharmaceuticals Corporation NVS | 6 | $133 |
| Tempus AI, Inc TEM | 1 | $119 |
| Merck Sharp & Dohme LLC MRK | 5 | $93.08 |
| Janssen Biotech, Inc. JNJ | 2 | $61.53 |
| Astellas Pharma US Inc 4503.T | 3 | $47.02 |
| Ipsen Biopharmaceuticals, Inc IPN.PA | 2 | $39.83 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.